January 16, 2025

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
  • German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors.

Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, entitled “New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumors)”, will be hosted at the BioMed X Institute in Heidelberg.

The goal of this partnership is to leverage the latest advances in multi-functional biologics, such as bi- and tri-specific antibodies, to develop new therapies that can engage multiple targets simultaneously within the tumor microenvironment. These next-generation therapies aim to overcome the limitations of conventional treatments by leveraging synergistic effects of different antitumor signaling pathways and mechanisms by manipulating proximity of multiple targets.

Call for Research Proposals

The BioMed X Institute and Daiichi Sankyo are inviting proposals from researchers around the world to participate in this ambitious project.

The MTT initiative focuses on the following key research challenges:

  • Development of new therapeutic concepts for bi- or multi-specific biologics for new extracellular or intracellular target combinations which could be exploited for the treatment of solid tumors.
  • Exploration, identification, and functional validation of promising new target combinations in vitro and in vivo.
  • Development of an elegant in vitro assay system for functional assessment of novel target combinations.

Researchers are encouraged to submit proposals that demonstrate originality, especially those supported by preliminary experimental data or utilizing state-of-the-art machine learning tools. The call is open to projects targeting any solid tumor indication. However, classical immune cell engagers, combination therapies, and other modalities outside peptides or proteins (e.g., small molecules, nucleic acids, gene or cell therapies) are not within the scope of this project.

The new research team will join seven other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2025-BMX-C01 before March 9, 2025.

Christian Tidona, Founder and Managing Director of the BioMed X Institute, commented: “Partnering with Daiichi Sankyo on the MTT project allows us to expand our research in oncology, focusing on next-generation biologics that can truly make a difference for cancer patients. This collaboration exemplifies our commitment to pioneering innovative therapeutic approaches.”


You can find the corresponding Job Applications here: https://biorn.org/discover-the-region/#biorn_projects_carrer

Our latest News

discover more
Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. In a mouse […]

ERC Awards Four Starting Grants to Universität Heidelberg

ERC Awards Four Starting Grants to Universität Heidelberg

European Research Council funds groundbreaking projects by early-career researchers The European Research Council is awarding four valuable grants to Heidelberg University. These ERC Starting Grants go to researchers in early stages of their career who want to carry out groundbreaking research with ERC funding. They include Dr Michael Gerlt, who will do research at the […]

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone will support the company’s growth and upscaling efforts, and provide the world’s largest HPL output, with 20,000L […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp